#Trends and Forecast by Disorder

[aarunresearcher]

The United States mental health market size was valued at USD 110 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 132 Billion by 2033, exhibiting a CAGR of 2.1% from 2025-2033. 

[kenresearch1]

Biosimilars Unleashed: The Future of Healthcare in the US

Buy Now

What is the Size of US Biosimilar Industry?

US Biosimilar Market is expected to grow at a CAGR of ~ % between 2017-2022 and is expected to reach ~USD Bn by 2028. Biosimilars enhance patient access to essential treatments, especially in therapies with high demand, like oncology, by providing more affordable options. Additionally, Growing evidence of biosimilars' comparable efficacy and safety fosters trust among healthcare professionals, driving adoption.

Click here to Download a sample Report

Biosimilars offer cost savings compared to originator biologics, addressing the need for affordable healthcare solutions in the face of rising medical costs. Favorable regulatory frameworks, like the BPCIA, streamline biosimilar approval processes, encouraging manufacturers to invest in development.

Furthermore, The expiration of patents for numerous reference biologics creates opportunities for biosimilar entry, leading to increased competition and market expansion. Pharmaceutical companies are investing in biosimilar R&D and production, expanding the pipeline and market availability. Supportive healthcare policies and reimbursement models incentivize biosimilar adoption, creating a favorable environment for market growth.

US Biosimilar Market by drug class

The US Biosimilar market is segmented by Monoclonal Antibodies, Recombinant Hormones, Immunomodulators, Anti-inflammatory agents and Others. Based on drug class, Monoclonal Antibodies segment dominates the bio similar market in 2022.

Monoclonal antibodies have diverse applications across various therapeutic areas. From cancer treatment to autoimmune diseases, biosimilar Mabs addressed a wide range of medical needs, leading to a broad and growing market. Biosimilars, with their potential for cost savings while maintaining comparable efficacy and safety, gained significant attention as viable alternatives.

US Biosimilar Market by application

In US Biosimilar market, they are segmented by application into Oncology, Blood disorders, Chronic diseases and autoimmune conditions and Others. On the basis of application, Oncology segment was the dominant in 2022.

The increasing prevalence of cancer and the high cost of traditional biologics used in oncology treatment have created a strong incentive for the adoption of biosimilars. Biosimilars offer the potential to provide similar therapeutic outcomes at a lower cost, making them an attractive option for both healthcare providers and patients.

Additionally, the rigorous clinical trials and regulatory processes that biosimilars undergo to gain approval provide reassurance to healthcare professionals and patients regarding their safety and efficacy. This has led to increased acceptance and adoption of biosimilars in oncology.

US Biosimilar by Region

The US Biosimilar market is segmented by Region into North, East, West and South. In 2022, the dominance region is North region in US Biosimilar market.

The North region benefits from a concentration of healthcare providers and academic institutions that are at the forefront of adopting and integrating biosimilars into their treatment protocols. These institutions are more likely to have the expertise to evaluate and incorporate biosimilars effectively, driving their adoption among healthcare professionals and patients.

Click here to Download a Custom Report

Competition Scenario in US Biosimilar Market

The US biosimilar market has witnessed an evolving competitive landscape, with several key players competing for market share. Prominent pharmaceutical companies such as Amgen, Pfizer, Sandoz (Novartis), and Boehringer Ingelheim have been actively involved in developing and marketing biosimilar products. These established players have utilized their expertise in biologics and significant resources to navigate the regulatory landscape and compete effectively.

The competition in the US biosimilar market is characterized by a balance between established pharmaceutical giants and emerging biotech companies. While the major players possess the advantage of resources and experience, smaller biotech firms are also contributing to the market with innovative approaches and niche biosimilar offerings.

What is the Expected Future Outlook for the Overall US Biosimilar Market?

The US Biosimilar market was valued at USD ~Million in 2022 and is anticipated to reach USD ~ Billion by the end of 2028, witnessing a CAGR of ~% during the forecast period 2022- 2028. The US biosimilar market is likely to experience significant growth in the coming years, driven by several factors. Biosimilars are biologic drugs that are highly similar to already approved reference biologics. They offer potential cost savings, increased competition, and improved patient access to crucial treatments.

Firstly, the regulatory environment is becoming more favorable for biosimilars. The Biologics Price Competition and Innovation Act (BPCIA) established a pathway for biosimilar approval in the US, allowing for a smoother regulatory process. As more biosimilars receive approval, competition in the market is expected to intensify.

Secondly, patents for several blockbuster biologics are expiring or have already expired. This creates opportunities for biosimilar manufacturers to enter the market with more affordable alternatives, offering healthcare systems and patients a choice in treatment options.

Thirdly, as healthcare costs continue to rise, biosimilars present an attractive solution for reducing expenses. Their potential to offer cost savings without compromising therapeutic efficacy could lead to increased adoption by healthcare providers, insurers, and patients alike.

Physician and patient education are crucial, as misconceptions about biosimilars' safety and effectiveness might hinder their adoption. Additionally, legal and market access barriers, including patent litigation and complex distribution systems, could slow down the growth of the biosimilar market.

The biosimilar market witness consolidation as larger pharmaceutical companies acquire or partner with smaller biotech firms to bolster their biosimilar portfolios. This will lead to more resources being devoted to biosimilar development and marketing. Changes in healthcare policies, such as reimbursement models and value-based care initiatives, can influence the biosimilar market's growth. Favourable policies that incentivize biosimilar adoption drives their market growth.

[rahulcmi]

Endometriosis Treatment Market Regional Analysis And Future Forecast 2022-2028

The Endometriosis Treatment Market has witnessed significant growth and advancements in recent years, and the period from 2022 to 2028 is projected to bring forth a promising landscape of regional developments and future prospects. Endometriosis, a chronic gynecological condition characterized by the abnormal growth of tissue similar to the lining of the uterus outside the womb, affects millions of women worldwide. As awareness and diagnosis of the condition continue to improve, the demand for effective treatments is driving the evolution of the market across various regions.

In North America, which has historically been at the forefront of medical innovations, substantial investments in research and development are expected to fuel the market's growth. The region boasts a well-established healthcare infrastructure and a high prevalence of endometriosis cases, resulting in a strong demand for advanced therapeutic solutions. Technological advancements, such as minimally invasive surgical techniques and personalized treatment options, are anticipated to shape the future of endometriosis management in North America.

Europe, characterized by its emphasis on healthcare accessibility and quality, is likely to witness a surge in endometriosis treatment initiatives. Collaborative efforts between pharmaceutical companies, research institutions, and healthcare providers are anticipated to lead to the development of novel treatment modalities. The region's regulatory environment and favorable reimbursement policies will play a pivotal role in fostering innovation and ensuring patient access to emerging therapies.

Asia Pacific, home to a significant portion of the global population, is poised to exhibit remarkable growth in the Endometriosis Treatment Market during the forecast period. Increasing awareness about women's health issues, coupled with rising disposable incomes and improving healthcare infrastructure, is projected to drive market expansion in this region. As governments and healthcare organizations focus on addressing unmet medical needs, the demand for effective endometriosis treatments is likely to soar.

Latin America and the Middle East & Africa regions are also expected to witness notable advancements in endometriosis treatment. Growing healthcare investments, coupled with a rising prevalence of endometriosis cases, will likely contribute to the expansion of treatment options in these regions. Collaborative efforts between international healthcare organizations and local stakeholders are crucial for optimizing patient care and outcomes.

Looking ahead, the Endometriosis Treatment Market is poised for transformative changes driven by scientific breakthroughs, technological innovations, and increased patient advocacy. The development of targeted therapies, hormone-based treatments, and non-invasive interventions holds the potential to revolutionize how endometriosis is managed. However, challenges such as diagnosis delays and limited awareness in certain regions must be addressed to ensure equitable access to these advancements.

The period from 2022 to 2028 is expected to witness a dynamic and promising landscape in the Endometriosis Treatment Market across various regions. The interplay of research and development, healthcare policies, and patient-centric approaches will shape the evolution of treatment options, ultimately improving the quality of life for millions of women affected by endometriosis worldwide.

[psychicsheeparcade]

Lactose Intolerance Market Growth, Opportunities and Industry Forecast Report 2034

Lactose intolerance is a digestive disorder where individuals cannot digest lactose, a sugar found in milk and dairy products. This has led to a significant demand for lactose-free products, including dairy alternatives and enzyme supplements, creating a thriving market. The lactose intolerance market is expected to see strong growth in the coming years, driven by rising lactose intolerance cases, particularly in Asia-Pacific, where a large percentage of the population is affected.

The  lactose intolerance Market related products, including lactose-free foods, beverages, and lactase supplements, has witnessed strong growth. The global lactose-free market was valued at around USD 12 billion in 2022 and is projected to reach USD 18-20 billion by 2030, growing at a compound annual growth rate (CAGR) of approximately 6-7%. The rising consumer awareness about the digestive issues associated with lactose intolerance is a key factor driving this growth.

Get a Sample Copy of Report, Click Here: https://wemarketresearch.com/reports/request-free-sample-pdf/global-lactose-intolerance-market/1521

Lactose Intolerance Market Drivers

Several factors are driving the growth of the lactose intolerance market:

Increasing Prevalence: Studies indicate that over 65% of the global population has some degree of lactose intolerance, leading to higher demand for solutions.

Rising Health Awareness: As more consumers seek to avoid gastrointestinal discomfort associated with lactose consumption, awareness campaigns and medical advice have led to a surge in demand for lactose-free products.

Dairy Alternatives: Growing interest in plant-based diets is pushing demand for lactose-free dairy alternatives like almond, soy, oat, and coconut milk. Veganism is another contributing factor here.

Product Innovations: Manufacturers are developing lactose-free dairy products, including milk, cheese, and yogurt, as well as supplements like lactase enzymes.

Lactose Intolerance Market Trends

Consumer Preference Shift: There has been a notable shift toward plant-based alternatives and lactose-free products as consumers seek more sustainable and healthy choices.

Fortification of Dairy Alternatives: Companies are fortifying plant-based products with nutrients like calcium, vitamin D, and protein to match the nutritional profile of traditional dairy.

Online Retail Growth: The rise of e-commerce platforms has made lactose-free products more accessible, increasing consumer convenience and fueling market growth.

Lactose Intolerance Market Challenges

Product Cost: Lactose-free products are often more expensive than their traditional counterparts, which can limit their appeal to cost-sensitive consumers.

Taste and Texture: Some consumers may still prefer the taste and texture of regular dairy products, which can make transitioning to lactose-free or plant-based alternatives challenging.

Lactose Intolerance Market Regional Analysis

North America and Europe are leading markets for lactose-free products, driven by well-established dairy industries and rising lactose intolerance awareness. The U.S. and Germany are key markets in these regions.

The Asia-Pacific region is expected to witness the highest growth, fueled by the high prevalence of lactose intolerance, particularly in countries like China, India, and Japan. The region’s large population, combined with increased disposable income and growing awareness of lactose intolerance, is propelling the market forward.

Lactose Intolerance Market Segmentation,

Product Type:

Lactose-Free Dairy Products: Milk, cheese, yogurt, ice cream.

Dairy Alternatives: Soy milk, almond milk, rice milk, oat milk.

Distribution Channel:

Supermarkets and Hypermarkets

Online Stores

Specialty Stores

Convenience Stores

Key companies profiled in this research study are,

Nestlé S.A.

Danone S.A.

The Coca-Cola Company (Fairlife)

Johnson & Johnson (Lactaid)

General Mills, Inc.

Valio Ltd.

Arla Foods amba

Dean Foods Company

Parmalat S.p.A.

Saputo Inc.

Conclusion

The Lactose Intolerance Market is poised for sustained growth, driven by increasing global awareness of lactose intolerance and the rising demand for lactose-free and dairy alternative products. As more individuals seek health-conscious, digestive-friendly, and sustainable options, the market for lactose-free dairy, plant-based alternatives, and lactase supplements will continue to expand. However, challenges such as product cost and taste preferences need to be addressed through innovation. With major industry players focusing on product development and fortification, the future of the lactose intolerance market appears promising, offering both consumers and businesses a wide range of opportunities.

[health-views-updates]

Magnetic Resonance Imaging (MRI) Market Forecast 2024-2032: Size, Share & Industry Trends

The Magnetic Resonance Imaging (MRI) Market Revenue was valued at USD 6.6 billion in 2023 and is projected to grow significantly, reaching USD 11 billion by 2031, with a steady CAGR of 6.6% during the forecast period from 2024 to 2031. This growth is attributed to increasing demand for advanced diagnostic imaging techniques, rising prevalence of chronic diseases, and technological advancements in MRI systems.

Key Market Drivers

The adoption of MRI technology continues to rise due to its superior diagnostic capabilities, non-invasive nature, and ability to provide detailed images of soft tissues, organs, and other internal body structures. Increasing incidences of neurological disorders, cardiovascular diseases, and cancer are further driving the need for accurate and early diagnosis, contributing to market expansion.

Recent advancements in MRI technology, including the development of 7-Tesla MRI systems, AI-driven imaging solutions, and portable MRI devices, have revolutionized diagnostic practices by improving image resolution, reducing scan times, and enhancing patient comfort. Furthermore, the integration of AI and machine learning in MRI is enabling automated image analysis and predictive diagnostics, offering a significant boost to market growth.

Regional Insights

North America dominates the global MRI market, owing to well-established healthcare infrastructure, high adoption rates of advanced imaging systems, and substantial R&D investments. Meanwhile, the Asia-Pacific region is expected to witness rapid growth due to rising healthcare expenditure, expanding medical tourism, and increased government initiatives to improve diagnostic capabilities.

Get Free Sample Report@ https://www.snsinsider.com/sample-request/2906

Market Outlook

As the demand for precise and non-invasive diagnostic imaging continues to grow, the MRI market is poised for substantial growth. Innovations such as hybrid imaging systems, enhanced contrast agents, and advancements in superconducting magnets are likely to create new opportunities for market players. The rising focus on healthcare accessibility in emerging economies is also expected to boost market penetration in the coming years.

About Us

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us

Akash Anand – Head of Business Development & Strategy Email: info@snsinsider.com Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)

[metastatblog]

Chronic Eye Diseases Market Analysis, Size, Share, Growth, Trends, and Forecasts by 2031

The Chronic Eye Diseases Market is a dynamic and multifaceted ecosystem, consisting of various stakeholders, each contributing their expertise and resources towards the common goal of enhancing eye health. 

𝐆𝐞𝐭 𝐚 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:https://www.metastatinsight.com/request-sample/2470

Top Companies

Novartis AG

AbbVie

Alcon

Akorn

Santen Pharmaceutical Co., Ltd.

Bausch & Lomb Incorporated

Kala Pharmaceuticals

Ocular Therapeutics

Regeneron Pharmaceuticals

OASIS Medical

Sun Ophthalmics

OCULUS Surgical

VISUfarma

Sentiss Pharma

Aerie Pharmaceuticals

This domain plays addresses the medical needs of millions of individuals worldwide who are grappling with conditions such as glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, and other ocular disorders that can significantly impact one's quality of life. 

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐭𝐡𝐞 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭:@https://www.metastatinsight.com/report/chronic-eye-diseases-market/2470

This essay delves into the Chronic Eye Diseases Market, offering insights into its composition, the challenges it faces, the evolving landscape, and the pivotal role it plays in ensuring the well-being of patients with chronic eye diseases.

Pharmaceutical companies are at the forefront, constantly innovating to develop new drugs and therapies to treat chronic eye diseases. These companies invest heavily in research and development to discover novel treatments and improve existing ones. Medications, such as anti-VEGF drugs for AMD or prostaglandin analogs for glaucoma, are prime examples of their contributions.

Medical device manufacturers also form an integral part of the market, producing cutting-edge tools and devices used in diagnostics, surgical procedures, and patient management. These innovations have revolutionized the way chronic eye diseases are diagnosed and treated, from advanced imaging techniques to minimally invasive surgical instruments.

Healthcare professionals, including ophthalmologists, optometrists, and retina specialists, are the linchpin of this market, as they provide clinical expertise and deliver personalized care to patients. Their role extends from early diagnosis to the long-term management of chronic eye diseases, ensuring that patients receive the best possible care.

Global Chronic Eye Diseases market is estimated to reach $11,219.7 Million by 2030; growing at a CAGR of 5.2% from 2023 to 2030.

Contact Us:   

inquiry@metastatinsight.com

+1 214 613 5758

[industrynewsupdates]

Medical Sensors Market Size, Share And Trends Analysis Report

The global medical sensors market size is expected to reach USD 142.2 billion by 2030, registering a CAGR of 19.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. it's upsurge in the number of patients afflicted with chronic conditions, such as diabetes and hypertension, is fueling the usage of monitoring as well therapeutic devices, thus boosting the market demand. 

The target population for this market is patients with chronic illnesses, as such conditions necessitate regular checkups and intermittent or continuous patient monitoring. The rise in population of chronically ill patients further increases the uptake of the medical sensors. 

The geriatric population is highly prone to developing chronic disorders and they pose a higher risk of developing age-related deformities and complications. Moreover, the adoption of unhealthy food habits and sedentary lifestyles and the resultant surge in the incidence of obesity has led to the increasing prevalence of lifestyle disorders including diabetes. The presence of a large target population base combined with the prevalence of lifestyle-related risk factors is likely to accelerate the growth of the medical sensors market during the forecast period. 

Gather more insights about the market drivers, restrains and growth of the Medical Sensors Market

Medical Sensors Market Report Highlights

• The biosensors products segment held a lucrative share of over 44.0% in 2023. This is ascribable to the following attributes of the novel biosensors: durability, reliability, and accuracy. Moreover, their applications in the healthcare areas, such as the detection of drug abuse, glucose monitoring for diabetes, the detection of cholesterol, and others. All these elements governed the growth of this segment in 2023. 

• The surgical applications of the sensors dominated the market in 2023. Whereas, the monitoring applications segment is projected to be the fastest growing during the forecast period. Advancements, such as wearable technology are anticipated to boost the demand for the monitoring devices market. 

• The hospitals registered a remunerative growth in 2023; this can be attributed to the presence of a well-developed healthcare infrastructure, which yields faster and accurate diagnosis. Moreover, the availability of well-equipped infrastructure coupled with the presence of skilled personnel and technologically advanced equipments contribute towards the lucrative growth of this segment. 

• North America held a considerably large share of over 34.6% in 2023 owing to the presence of leading sensor manufacturers, a well-planned medical reimbursement network, and the increasing disposable income 

• On the contrary, Asia Pacific is anticipated to be the fastest growing region with a CAGR of over 20.6% over the forecast period. The favorable economic developments and the advancing healthcare system with the aid of supportive government initiatives are anticipated to further assist the growth. Moreover, the increasing base of the aging population in this region also, additionally impels the demand. According to the report published by the Ministry of Statistics, in India, 8.6% of the total population is aged above 60; hence, presenting a profitable opportunity for the market players to invest in this region.

Medical Sensors Market Segmentation

Grand View Research has segmented the global medical sensors market based on product, application, end use, and region:

Medical Sensors Product Outlook (Revenue, USD Million, 2018 - 2030)

• Pressure Sensors

• Temperature Sensor

• Image Sensors

• Accelerometer

• Biosensors

o Cholesterol

o Blood Glucose

o Blood Gas Analyzers

o Pregnancy testing

o Drug Discovery

o Infectious Diseases

• Flow Sensors

• Squid Sensors

• Others

Medical Sensors Application Outlook (Revenue, USD Million, 2018 - 2030)

• Surgical

• Diagnostics

• Therapeutics

• Monitoring

Medical Sensors End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital

• Stand Alone clinics

• Nursing Homes

• Home Healthcare

• Others

Medical Sensors Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

o Mexico

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o China

o India

o Japan

o Australia

o South Korea

o Thailand

• Latin America

o Brazil

o Argentina

• Middle East and Africa (MEA)

o Saudi Arabia

o South Africa

o UAE

o Kuwait

Order a free sample PDF of the Medical Sensors Market Intelligence Study, published by Grand View Research.

[global-research-report]

Market Dynamics of Home Healthcare in North America: Opportunities Ahead

The North America home healthcare market size is expected to reach USD 285.05 billion by 2030, registering a CAGR of 7.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising aging human population, high disposable income for healthcare expenditure, and increasing rate of target diseases are some of the key factors driving growth. Predominance of chronic diseases, and increasing diagnosis expenditure is anticipated to boost growth. 

Personalized medical assistance is a cost effective measure to control treatment expenditure and acts as a major driver for the industry. According to America’s Health rankings, nearly 58 million adults aged 65 and older lived in the U.S. in 2022.

The home healthcare industry is anticipated to be majorly driven by the huge aging population volume which is highly prone to various diseases such as venous stasis ulcers, diabetic ulcers, and pressure ulcers. According to WHO, the global volume of population falls under the age group of 60 years and above has reached 841 million in 2014 and is expected to reach 2 billion by 2050. Therefore, rising global aging-population along with the statistics that approximately 70% of home healthcare patients belong to 65 years and above age group, is anticipated to fuel demand in the near future.

Wound care accounted for 65% of the global market revenue in 2014. Substantial demand for wound closures, wound care dressings, and wound cleanser has resulted in the dominance of the segment over the past few years and this trend is expected to continue over the forecast period. Wound infection is a key safety concern for medical professionals and patients, thus the market is anticipated to fuel the demand as it compelled to reduce the infection rates. Wound care products improve the overall health of patients affected from various disorders such as, diabetic ulcers, pressure ulcers and venous stasis ulcers, therefore creating strong need for these products in the industry.

Rising number of geriatric patients with growing awareness about personal safety and hygiene is further expected to intensify home healthcare service demand in North America. Baxter offers broad solutions to empower healthcare professionals to offer personalized care. It offers products for healthcare professionals for hospital care, primary care, kidney care, surgical care, nutritional care and others.

The services segment accounted for the largest market share of 84.1% in 2023. The segment is further divided into skilled and unskilled homecare. Different services such as nutritional support, nursing care, hospice & palliative, physician primary care, and others are offered by home healthcare services. The accurate diagnosis and medical treatment offered by skilled healthcare is attributing the segment growth. On the other hand, the equipment segment is expected to register the fastest CAGR of 8.6% during the forecast period. The segment is divided into therapeutic, diagnostic, and mobility assist segments.

The U.S. home healthcare market dominated the North America market with a share of 90.0% in 2023 due to advanced healthcare infrastructure. Large base of aging population, growing healthcare infrastructure and high purchasing power are some of the key factors driving growth. Moreover, favorable government initiatives aimed at controlling treatment expenditure by promoting home care services are anticipated to fuel growth. According to the PRB (Population Reference Bureau), at present, approximately 50 million citizens of North America are over 65 years and the number is projected to reach 89 million by 2050.

North America Home Healthcare Market Report Highlights

The services segment accounted for the largest market share of 84.1% in 2023. The segment is further divided into skilled and unskilled homecare.

The equipment segment is expected to register the fastest CAGR of 8.6% during the forecast period. The segment is divided into therapeutic, diagnostic, and mobility assist segments.

The diabetes & kidney disorders segment accounted for the largest market share in 2023. According to American Diabetes Association, 38.4 million Americans were diagnosed with diabetes in 2021.

The mobility disorders segment is projected to grow at the fastest CAGR over the forecast period.

North America Home Healthcare Market Segmentation

Grand View Research has segmented global North America Home Healthcare market report based on component, indication, and region:

North America Home Healthcare Component Outlook (Revenue, USD Million, 2018 - 2030)

Equipment

Therapeutic

Home Respiratory Equipment

Insulin Delivery Market

Home IV Pumps

Home Dialysis Equipment

Other Therapeutic Equipment

Diagnostic

Diabetic care unit

BP monitors

Multi para diagnostic monitors

Home pregnancy and fertility kits

Apnea and sleep monitors

Holter monitors

Heart rate meters(include pacemakers)

Other

Mobility Assist  

Wheel chair

Home medical furniture

Walking assist devices

Services

Skilled Home Healthcare

Physician Primary Care

Nursing Care

Physical/occupational/speech therapy

Nutritional Support

Hospice & Palliative

Other skilled nursing services

Unskilled Home Healthcare

North America Home Healthcare Indication Outlook (Revenue, USD Million, 2018 - 2030)

Cardiovascular Disorder & Hypertension

Diabetes & Kidney Disorders

Neurological & Mental Disorders

Respiratory Disease & COPD

Maternal Disorders

Mobility Disorders

Cancer

Wound Care

Others

North America Home Healthcare Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

S.

Canada

Mexico

Order a free sample PDF of the North America Home Healthcare Market Intelligence Study, published by Grand View Research.

[govindtbrc]

Levodopa Market: Key Trends and Developments in Parkinson’s Disease Treatment up to 2033

Market Definition The Levodopa Market centers around the production and distribution of levodopa, a critical medication used primarily for the treatment of Parkinson’s disease and dopamine-responsive dystonia. As the gold-standard treatment for Parkinson’s disease, levodopa works by converting to dopamine in the brain, replenishing the neurotransmitter that becomes deficient in patients suffering from this degenerative neurological disorder. Available in various formulations, including oral tablets, capsules, and combination drugs (such as carbidopa-levodopa), levodopa remains a vital therapeutic option.

To Know More @ https://www.globalinsightservices.com/reports/levodopa-market

The global Levodopa market is anticipated to expand from $4.2 billion in 2023 to $7.5 billion by 2033, reflecting a compound annual growth rate (CAGR) of 5.8%.

Market Outlook The Levodopa Market is poised for steady growth, driven by the increasing prevalence of Parkinson’s disease worldwide and the ongoing demand for effective treatments. The aging global population is a significant factor contributing to the rising incidence of Parkinson’s, as the disease is more common among older adults. As awareness of neurological disorders improves and diagnostic capabilities advance, more patients are being identified, further boosting the demand for levodopa-based therapies.

A key trend in the market is the development of new formulations and delivery methods aimed at enhancing the efficacy and patient adherence of levodopa treatment. Continuous research is underway to optimize the absorption and bioavailability of levodopa, as well as to reduce its side effects, such as motor fluctuations and dyskinesia. Innovative delivery systems, such as intestinal gel formulations and extended-release capsules, are being explored to provide more consistent symptom control.

Pharmaceutical companies are also investing in combination therapies that incorporate levodopa with other drugs to improve therapeutic outcomes. For example, adding enzyme inhibitors like entacapone or carbidopa helps to prevent the breakdown of levodopa before it reaches the brain, enhancing its effectiveness and reducing the required dosage. These advancements are crucial in improving the quality of life for Parkinson’s patients, who often experience a decline in treatment efficacy over time.

However, the market faces challenges related to the side effects and long-term complications of levodopa therapy. The development of motor complications, such as dyskinesia and the “on-off” phenomenon, remains a concern, prompting ongoing research into alternative treatment strategies and adjunctive therapies. Additionally, the high cost of advanced levodopa formulations can be a barrier for patients in low- and middle-income countries, where access to quality healthcare remains limited.

Request the sample copy of report @ https://www.globalinsightservices.com/request-sample/GIS32379

Research Objectives

Estimates and forecast the overall market size for the total market, across product, service type, type, end-user, and region

Detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling

Identify factors influencing market growth and challenges, opportunities, drivers and restraints

Identify factors that could limit company participation in identified international markets to help properly calibrate market share expectations and growth rates

Trace and evaluate key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities

Thoroughly analyze smaller market segments strategically, focusing on their potential, individual patterns of growth, and impact on the overall market

To thoroughly outline the competitive landscape within the market, including an assessment of business and corporate strategies, aimed at monitoring and dissecting competitive advancements.

Identify the primary market participants, based on their business objectives, regional footprint, product offerings, and strategic initiatives

Request For Report Customization @ https://www.globalinsightservices.com/request-customization/GIS32379

Market Segmentation

In 2023, the Levodopa market volume was estimated at 320 million units, with projections to reach 500 million units by 2033. The oral administration segment dominates the market, holding a 55% share, while the injectable segment follows with 30%. The transdermal segment, although smaller at 15%, is experiencing rapid growth due to advancements in drug delivery systems. The demand for Levodopa is primarily driven by its effectiveness in managing Parkinson’s disease symptoms, with North America and Europe being the largest consumers due to high prevalence rates and advanced healthcare infrastructure.

Competitive dynamics are heavily influenced by key players such as AbbVie Inc., Merck & Co., and Teva Pharmaceutical Industries. These companies leverage strategic collaborations and R&D investments to maintain market leadership. Regulatory frameworks, particularly those by the FDA and EMA, significantly impact market strategies, focusing on drug safety and efficacy. Future projections indicate a 10% annual growth rate, driven by an aging population and increased awareness of neurological disorders. However, stringent regulations and high R&D costs remain challenges. The integration of AI in drug development and personalized medicine approaches is expected to offer new growth opportunities in the Levodopa market.

Major Players

Mylan

Teva Pharmaceutical Industries

Sun Pharmaceutical Industries

Cipla

Zydus Cadila

Aurobindo Pharma

Torrent Pharmaceuticals

Alkem Laboratories

Lupin Pharmaceuticals

Dr Reddy’s Laboratories

Wockhardt

Intas Pharmaceuticals

Glenmark Pharmaceuticals

Hikma Pharmaceuticals

Apotex

Amneal Pharmaceuticals

Endo International

Perrigo Company

Mallinckrodt Pharmaceuticals

Lannett Company

Request For Discounted Pricing @ https://www.globalinsightservices.com/request-special-pricing/GIS32379

Research Scope

Scope – Highlights, Trends, Insights. Attractiveness, Forecast

Market Sizing – Product Type, End User, Offering Type, Technology, Region, Country, Others

Market Dynamics – Market Segmentation, Demand and Supply, Bargaining Power of Buyers and Sellers, Drivers, Restraints, Opportunities, Threat Analysis, Impact Analysis, Porters 5 Forces, Ansoff Analysis, Supply Chain

Business Framework – Case Studies, Regulatory Landscape, Pricing, Policies and Regulations, New Product Launches. M&As, Recent Developments

Competitive Landscape – Market Share Analysis, Market Leaders, Emerging Players, Vendor Benchmarking, Developmental Strategy Benchmarking, PESTLE Analysis, Value Chain Analysis

Company Profiles – Overview, Business Segments, Business Performance, Product Offering, Key Developmental Strategies, SWOT Analysis

For In-Depth Competitive Analysis, Buy Now @ https://www.globalinsightservices.com/checkout/single_user/GIS32379

About Us

With Global Insight Services, you receive:

10-year forecast to help you make strategic decisions

In-depth segmentation which can be customized as per your requirements

Free consultation with lead analyst of the report

Infographic excel data pack, easy to analyze big data

Robust and transparent research methodology

Unmatched data quality and after sales service

Contact Us:

Global Insight Services LLC

16192, Coastal Highway, Lewes DE 19958

E-mail: info@globalinsightservices.com

Phone: +1-833-761-1700

Website: https://www.globalinsightservices.com/

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

[credenceresearchdotblog]

The Insoluble Dietary Fiber Market is projected to grow from USD 2891.5 million in 2024 to an estimated USD 5932.82 million by 2032, with a compound annual growth rate (CAGR) of 9.4% from 2024 to 2032.The Insoluble Dietary Fiber Market is experiencing robust growth, driven by increasing consumer awareness about the health benefits of dietary fiber and its role in maintaining digestive health. Insoluble dietary fibers, found in whole grains, vegetables, fruits, and legumes, are essential for promoting gut health and preventing conditions like constipation, diverticulosis, and other gastrointestinal disorders. These fibers do not dissolve in water but add bulk to the stool, facilitating smooth bowel movements. Their rising inclusion in food and beverage formulations, coupled with growing health-consciousness among consumers, has positioned the market for significant expansion.

Browse the full report https://www.credenceresearch.com/report/insoluble-dietary-fiber-market

Market Dynamics: Growth Drivers and Trends

Health Awareness and Demand for Functional Foods

One of the key drivers of the insoluble dietary fiber market is the increasing prevalence of lifestyle-related disorders, such as obesity, diabetes, and cardiovascular diseases. Consumers are seeking functional foods and beverages enriched with dietary fibers to manage weight, regulate blood sugar levels, and improve overall health. Insoluble fibers, such as cellulose, hemicellulose, lignin, and resistant starch, are widely used in various food products, including bread, cereals, and nutritional bars, owing to their proven health benefits.

Rising Geriatric Population

The global aging population is another factor fueling market growth. Older adults are more prone to digestive issues, and incorporating insoluble fiber into their diets can alleviate these problems, promoting a healthy digestive system. This demographic shift has increased the demand for fiber-enriched products designed specifically for senior citizens.

Clean Label and Plant-Based Trends

The market is also benefiting from the increasing demand for clean-label and plant-based products. Insoluble dietary fibers are naturally sourced, aligning well with consumer preferences for natural, non-GMO, and allergen-free ingredients. This trend has spurred innovations in product formulations, encouraging manufacturers to develop plant-based food and beverage options enriched with dietary fiber.

Key Applications Across Industries

Food and Beverages

The food and beverage industry accounts for a significant share of the insoluble dietary fiber market. These fibers are widely used in bakery products, cereals, snacks, and beverages to enhance texture, extend shelf life, and improve nutritional value. Fiber-enriched products are increasingly popular among health-conscious consumers, particularly those focused on weight management and maintaining digestive health.

Pharmaceutical and Nutraceutical

Insoluble dietary fibers are gaining traction in the pharmaceutical and nutraceutical sectors, where they are incorporated into supplements and functional foods for their health-promoting properties. The fibers aid in lowering cholesterol levels, improving blood sugar regulation, and reducing the risk of chronic diseases. This has created a strong demand for fiber-based supplements in the global health and wellness market.

Animal Feed

The use of insoluble dietary fiber in animal feed is another growing application. These fibers improve the digestive health of livestock and pets, enhancing nutrient absorption and overall productivity in animals. The increasing focus on sustainable and high-quality animal feed is driving this segment’s growth.

Future Outlook and Challenges

The insoluble dietary fiber market is poised for sustained growth, with advancements in food processing technologies and innovations in fiber extraction methods. However, challenges such as the high cost of raw materials and potential side effects of excessive fiber intake may hinder market growth to some extent. Despite these challenges, the market is expected to thrive as consumers increasingly prioritize digestive health and wellness.

Key Player Analysis:

ADM (U.S.)

AdvoCare (U.S.)

Cargill, Incorporated (U.S.)

DuPont (U.S.)

Grain Processing Corporation (U.S.)

Ingredion (U.S.)

RETTENMAIER & SÖHNE GmbH + Co KG (Germany)

Nexira (France)

Roquette Frères (France)

SunOpta (Canada)

Tate & Lyle (U.K.)

Segmentation:

By Product Type:

Hemicellulose

Cellulose

Resistant Starch

Lignin

Chitosan & Chitin

Bran

Others

By Source:

Vegetables

Legumes

Grains & Cereals

Others

Fruits

Citrus Fruits

Exotic Fruits

Others

By Application:

Dietary Supplements & Pharmaceuticals

Beverages & Functional Food

Pet Food

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report https://www.credenceresearch.com/report/insoluble-dietary-fiber-market

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[kenresearch1]

Top 5 players in US Biosimilar Market

Buy Now

STORY OUTLINE

Pfizer: Excelling in the line of Biosimilar drugs with an experience of more than 10 years with presence in over 180 countries.

Amgen: Making pharmaceutical products with an experience of over 40 years and presence in over 100 countries.

Viartis: Presence in over 165 countries, and making Biosimilar drugs in over 75 markets, this pharmaceutical company is another leading contributor of US Biosimilar market.

Coherus Biosciences: Increasing patient access to cost effective medicines with a Biosimilar drugs experience of 13 years.

Biogen: serving humanity through science with a experiences of more than 40 years in the field of biologics.

According to Ken Research, the US Biosimilar market is anticipated to grow at a CAGR of ~40% in the next five years which currently has a market size of ~USD 9.4 Bn.

The US Biosimilar market is rapidly growing and will be witnessing a significant growth in the next five years.

There are various reasons behind the rapid growth of US Biosimilar market. Some of the major reasons behind the growth of US Biosimilar market include the cost effective nature of Biosimilar drugs, rising geriatric population, rising prevalence of chronic diseases, and growing partnerships between companies to develop Biosimilar drugs.

Various companies and players are contributing to their best efforts in the growth of the US Biosimilar market.

This article aims to put light on the contributions done by the major players towards the growth of the US Biosimilar market.

1.Pfizer

Click to read more about Pfizer

Pfizer is a leading American pharmaceutical company which is operating in the field of generics or original drugs for more than 30 years. But did you know that this pharma not only manufactures biologics but also biosimilar drugs?

Pfizer has been in the business of biosimilar drugs for more than 10 years and have been quite successful as well. With more than 83,000 employees and presence in over 180 countries, this leading pharmaceutical company made almost USD 2 Bn. revenue only from its Biosimilar drugs sale in 2021.

Recently, this pharmaceutical company also collaborated with Samsung in two deals to produce various biosimilar drugs in South Korea. The deal size between these two companies happens to be approximately USD 900 Bn.

The major Biosimilar drugs of this pharmaceutical giant are primarily

ZIRABEV (a Biosimilar of Avastin)

TRAZIMERA (a Biosimilar of Herceptin)

RUXIENCE (a Biosimilar of Rituxan)

RITACRIT (a Biosimilar of Epogen)

NVYEPRIA (a Biosimilar of Neulasta)

NIVESTYM (a Biosimilar of Neupogen)

FILGRASTIM (a Biosimilar of Neupogen).

2.Amgen

Click here to Download a Sample Report

Amgen is another leading American pharmaceutical company which not only makes Biologics or generic drugs but also Biosimilar drugs. This pharmaceutical company has more than 40 years of experience when it comes to pharmaceutical line.

With over 25000 employees and presence in over 100 countries, this pharmaceutical company earned about USD 2 Bn. from their three biosimilar drugs which are reportedly MVASI, KANJITNTI, and AMJEVITA.

This pharma giant has also invested about USD 2 Bn. in the development of Biosimilar drugs.

This pharmaceutical company has made Biosimilar drugs primarily in 4 fields which are General Medicine, Oncology, and Hematology along with, Inflammation.

EPOTEIN ALFA

AMJEVITA

AVSOLA

KANJINTI

MVASI

RIABNI

are the various Biosimilar drugs of Amgen. And, STELARA, EYLEA, SOLIRIS are in their pipeline.

Recently Amgen revealed their Biosimilar report’s 8 version. It revealed a major information which said that the pharmaceutical company saved about USD 10 Bn. through their Biosimilar drugs in the past five years.

3.Viartis

Headquartered in Canonsburg, Pennsylvania, this American pharmaceutical company was founded only in 2020 yet they have achieved massive success in the pharmaceutical products with their revenue being USD 16 ~Bn. in 2022.

With presence in 165 countries and with over 45,000 employees worldwide, this pharmaceutical company makes pharmaceutical products in 10 areas which primarily are Cardiovascular, Dermatology, ophthalmology, Oncology, Gastroenterology, Women’s health, Infectious diseases, Diabetes & Metabolism, Immunology, CNS & Anesthesiology, Respiratory diseases and allergy.

Speaking of their first Biosimilar products, their first ever Biosimilar drug was launched in 2014. They have a variety of Biosimilar drugs which are primarily

TRASTUZUMAB

INSULIN ASPART

PEGFILGRASTIM

INSULIN GLARGINE-YFGN

ADALIMUMAB

BEVACIZUMAB

Their Biosimilar drug Insulin Glargine which is known as SEMGLEE was the first ever interchangeable Biosimilar drug in the United States which was FDA approved.

Their PEGFILGRASTIM also was the first ever FDA approved drug in the United States. They have launched their Biosimilar drugs in over 75 markets worldwide.

4.Coherus Biosciences:

Click here to Ask for a Custom Report

Headquartered in Redwood city, California this American pharmaceutical company earned a revenue of almost USD 211 Mn. In 2022.

With presence in over 55 countries and 300+ employees worldwide, this pharmaceutical company makes products in various areas such as solid tumors, non-small lung cancers, nasopharyngeal carcinoma, small cell lung cancer and hepatocellular carcinoma.

Speaking of their Biosimilar drugs, this pharma has been in the field of creating Biosimilar drugs since 2010 which has given them almost 13 years of experience.

This pharmaceutical company also disclosed that it plans to spend at least USD 1 Tn. on medicines worldwide, out of which at least 40% will be spent on Biosimilar drugs.

Their three major Biosimilar drugs which are also FDA approved include UDENCYA, YUSIMRY, and CIMERLI.

Udencya is a Biosimilar drug of Pegfilgrastim, Yusimry is a Biosimilar drug of Ranibizumab, and Cimerli is a Biosimilar drug of Adalimumab.

5.Biogen

Headquartered in Cambridge, Massachusetts, this American pharmaceutical company earned a revenue of around USD 10 Bn. in 2022.

This company happens to have an experience of more than 40 years when it comes to making pharmaceutical products.

With presence in over 80 countries and more than 9000 employees worldwide, this pharmaceutical company primarily deals in Neurology, Specialized Immunology, Neuropsychiatry, Ophthalmology, and Rare Diseases.

ADUCANUMAB

LECANEMAB

TOFERSEN

ZURANOLONE

LITIFILIMAB

BENAPALI

FLIXABI

IMRALDI

are some of their Biosimilar drugs.

With their Biosimilar drugs, more than 250,000 people have gone on Anti-Tumor Necrosis Factor therapy.

Recently, this pharmaceutical company also made an agreement with Bio-Thera solutions to develop a Biosimilar drug for the treatment of Rheumatoid Arthritis.

[health-views-updates]

2024-2032 Sleep Apnea Devices Market Outlook: Revenue, Trends, and Growth

The Sleep Apnea Devices Market Revenue was valued at USD 4.69 billion in 2023 and is projected to expand significantly, reaching USD 7.82 billion by 2031. With a steady CAGR of 6.60% during the forecast period of 2024-2031, the market is driven by increasing awareness of sleep disorders, advancements in medical technology, and the rising prevalence of obstructive sleep apnea (OSA).

Key Market Dynamics

The global rise in the prevalence of sleep apnea, attributed to factors such as obesity, aging populations, and sedentary lifestyles, has amplified the demand for effective diagnostic and therapeutic devices. Moreover, heightened awareness campaigns about the health risks associated with untreated sleep apnea are encouraging individuals to seek timely diagnosis and treatment.

Technological advancements, including the development of portable, user-friendly, and highly efficient Continuous Positive Airway Pressure (CPAP) devices, are revolutionizing patient care. Additionally, the integration of digital health technologies and AI-powered solutions is enabling real-time monitoring and data-driven treatment personalization, significantly enhancing patient outcomes.

Regional Insights

North America leads the market due to high awareness levels, favorable reimbursement policies, and the strong presence of key industry players. Europe and the Asia-Pacific region are also witnessing substantial growth, driven by increasing healthcare investments, rising disposable incomes, and government initiatives to improve healthcare accessibility and awareness of sleep disorders.

Get Free Sample Report@ https://www.snsinsider.com/sample-request/2905

Market Opportunities

The growing focus on minimally invasive and non-invasive treatment options presents lucrative opportunities for industry players. Moreover, the shift toward home healthcare and the rising adoption of wearable sleep monitoring devices are expected to further propel market growth. Partnerships between technology providers and healthcare organizations are fostering the development of innovative and cost-effective solutions, ensuring broader market penetration.

About Us

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us

Akash Anand – Head of Business Development & Strategy Email: info@snsinsider.com Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)

[hariganesh858]

Orthopaedic Implants Market

Orthopaedic Implants Market Size, Share, Trends: Zimmer Biomet Leads

Increasing Prevalence of Orthopaedic Disorders Driving Market Growth

Market Overview: 

The global orthopaedic implants market is projected to grow at a CAGR of YY% during the forecast period of 2024-2031, reaching a market size of USD YY billion by 2031 from USD XYZ billion in 2024. North America is expected to dominate the market, driven by the increasing prevalence of orthopaedic disorders, rising geriatric population, and growing adoption of advanced orthopaedic implants. The growth of the orthopaedic implants market is fueled by factors such as the rising incidence of sports injuries and road accidents, growing healthcare expenditure, and technological advancements in orthopaedic implants. However, the high cost of orthopaedic implants and the risk of implant failure may restrain the market growth to some extent.

The growing frequency of orthopaedic illnesses, such as osteoarthritis, rheumatoid arthritis, and osteoporosis, is a major driver of the orthopaedic implants industry. According to the World Health Organisation (WHO), musculoskeletal problems impact over 1.7 billion people worldwide and are the major cause of disability. The growing geriatric population, changing lifestyles, and rising obesity rates all contribute to an increased burden of orthopaedic problems, driving demand for orthopaedic implants. Manufacturers are focussing on developing innovative, patient-specific implants to meet the unique needs of orthopaedic patients.

DOWNLOAD FREE SAMPLE

Market Trends: 

Technological improvements in orthopaedic implants, such as 3D-printed implants, robot-assisted surgery, and smart implants, are major market drivers. These developments provide various advantages, including greater implant fit and lifespan, shorter surgical times and problems, and better patient outcomes. For example, 3D-printed implants allow for the development of patient-specific implants that fit the individual's anatomy, leading in improved implant stability and faster recovery. The growing use of these advanced technologies by healthcare professionals is projected to propel the orthopaedic implants market in the approaching years.

Despite the various advantages, the high cost of orthopaedic implants may limit market expansion, especially in emerging countries and among price-sensitive patients. Orthopaedic implants, particularly those constructed of sophisticated materials or utilising cutting-edge technology, are often expensive. The cost of these implants can be too expensive for those who lack proper health insurance coverage or have limited financial resources. Furthermore, payment rules for orthopaedic implants differ by country and insurance provider, affecting the pricing and accessibility of these devices.

Market Segmentation: 

The joint reconstruction category, which comprises hip, knee, and shoulder implants, is likely to dominate the orthopaedic implants market during the forecast period. The increasing frequency of osteoarthritis, the growing geriatric population, and the growing demand for minimally invasive joint replacement surgeries all contribute to the segment's rise. According to the American Academy of Orthopaedic Surgeons (AAOS), over 7 million Americans have had total joint replacement surgery, and the demand for these treatments is likely to rise dramatically in the future years.

Major orthopaedic implant manufacturers, including Zimmer Biomet, DePuy Synthes (Johnson & Johnson), and Stryker Corporation, are investing heavily in the development of advanced joint reconstruction implants, such as 3D-printed and robot-compatible implants, to meet rising demand and improve patient outcomes. For example, in 2023, Zimmer Biomet introduced a new range of 3D-printed hip implants that provide better bone ingrowth and long-term stability than traditional implants.

Market Key Players:

Zimmer Biomet

DePuy Synthes (Johnson & Johnson)

Stryker Corporation

Smith & Nephew plc

Medtronic plc

NuVasive, Inc.

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/

[industrynewsupdates]

Exploring Glioblastoma Multiforme Treatment Market : Trends and Future Outlook

The global glioblastoma multiforme treatment market size is expected to reach USD 5.10 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.7% from 2023 to 2030. The market is driven by the rising prevalence of the disease and increasing approval for novel therapy and combination therapy.

In recent years, the industry has been growing rapidly owing to the introduction of innovative products and rising interest of major pharmaceutical companies in the market due to favorable guidelines and rising incidence of the disease. For instance, companies such as Bristol Myers Squibb; CNS Pharmaceuticals, Inc.; and Bayer have novel products in the pipeline for glioblastoma multiforme. These products are likely to boost competitive rivalry in the market in the coming years.

Moreover, companies are collaborating to develop novel treatments. For instance, in October 2019, Advaxis, Inc., a clinical-stage biotechnology company, announced a research collaboration agreement with the University of California for the development and commercialization of novel immunotherapy by using the company’s Lm Technology in mouse tumor models of glioblastoma multiforme. An increase in collaborations between researchers and market players is expected to boost the development of novel and effective treatment options for glioblastoma multiforme.

Existing companies are willing to acquire new companies with pipeline products to diversify their product portfolio. For instance, in May 2019, Merck announced the upfront USD 1.1 billion acquisition of Peloton Therapeutics, which grants it access to the PT2977 under trial glioblastoma drug. This acquisition is likely to strengthen its pipeline and improve its future revenue-generation ability.

Gather more insights about the market drivers, restrains and growth of the Glioblastoma Multiforme Treatment Market

Glioblastoma Multiforme Treatment Market Report Highlights

• Based on treatment, in 2020, radiation therapy dominated the market with a revenue share of 37.0% in 2022, owing to improved survival rates, as radiation therapy is most often recommended as the first line of treatment or in combination with chemotherapy and surgery

• By drug class, the others segment accounted for the largest revenue share in 2022. The segment includes everolimus, corticosteroids, and 5-aminolevulinic acid (5-ALA)

• The hospital segment held the largest revenue share in the glioblastoma multiforme treatment market in 2022 and is anticipated to maintain its leading position during the forecast period. Patients prefer hospitals in terms of treatment accessibility and convenience

• Asia Pacific is expected to register the fastest growth rate of 11.1% over the forecast period, owing to various factors such as the entry of generics of temozolomide in the market, improving economy, rising geriatric population, and growing investments in the healthcare sector

• North America accounted for the largest share of 43.4% in 2022. Government support for the development of the healthcare sector, high awareness about rare disorders, easy accessibility to quality medical facilities, and favorable reimbursement policies are among the key factors responsible for the regional market growth

Glioblastoma Multiforme Treatment Market Segmentation

Grand View Research has segmented the global glioblastoma multiforme treatment market on the basis of treatment, drug class, end-use, and region:

Glioblastoma Multiforme Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• Surgery

• Radiation Therapy

• Chemotherapy

• Targeted Therapy

• Tumor Treating Field (TTF) Therapy

• Immunotherapy

Glioblastoma Multiforme Treatment Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Temozolomide

• Bevacizumab

• Lomustine

• Carmustine Wafers

• Others

Glioblastoma Multiforme Treatment End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Clinics

• Ambulatory Surgical Centers

Glioblastoma Multiforme Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa

o Saudi Arabia

o South Africa

o UAE

o Kuwait

Order a free sample PDF of the Glioblastoma Multiforme Treatment Market Intelligence Study, published by Grand View Research.